Domain III of the envelope protein as a dengue vaccine target

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

(2010) Wellington Sun et al.   Human vaccines & immunotherapeutics

Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice

(2009) L. Gil et al.   INTERNATIONAL IMMUNOLOGY

Passage of Dengue Virus Type 4 Vaccine Candidates in Fetal Rhesus Lung Cells Selects Heparin-Sensitive Variants That Result in Loss of Infectivity and Immunogenicity in Rhesus Macaques

(2009) G. Anez et al.   JOURNAL OF VIROLOGY

Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens

(2009) Wayne D. Crill et al.   PLoS One

An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity

(2009) Saima Khanam et al.   VACCINE

A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice

(2009) Iris Valdés et al.   VIROLOGY

Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody

(2009) W.M.P.B. Wahala et al.   VIROLOGY

Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates

(2008) L BERNARDO et al.   ANTIVIRAL RESEARCH

Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins

(2008) Lidice Bernardo et al.   ARCHIVES OF VIROLOGY

Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice

(2008) Laura Lazo et al.   BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY

Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus

(2008) G. D. Gromowski et al.   JOURNAL OF VIROLOGY

A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity

(2008) Chih-Hsiang Leng et al.   MICROBES AND INFECTION

Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins

(2008) Shee-Mei Lok et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987–2007

(2008) Maria G. Guzman et al.   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

(2008) Bruno Guy et al.   VACCINE

Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen

(2008) Adrian C.N. Sim et al.   VACCINE

Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice

(2008) J. Pradeep Babu et al.   VACCINE

Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis

(2008) Iris Valdés et al.   VACCINE

Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells

(2008) Vivian Huerta et al.   VIRUS RESEARCH

Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus

(2008) Alienys Izquierdo et al.   VIRUS RESEARCH

Recombinant vector derived from live attenuated measles virus: Potential for flavivirus vaccines

(2007) Samantha Brandler et al.   COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES